Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $60.88, for a total transaction of $243,520.00. Following the completion of the sale, the director now directly owns 82,394 shares of the company’s stock, valued at approximately $5,016,146.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Monday, October 16th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.09, for a total transaction of $71,090.00.
  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.10, for a total transaction of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total transaction of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.59, for a total transaction of $262,360.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00.

Agios Pharmaceuticals, Inc. (AGIO) traded down $2.50 on Wednesday, reaching $59.46. 453,600 shares of the company traded hands, compared to its average volume of 529,215. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm’s revenue was up 26.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.63) EPS. equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Lewis Clayton Jr. Cantley Sells 4,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/15/lewis-clayton-jr-cantley-sells-4000-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

AGIO has been the subject of a number of analyst reports. BidaskClub lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Royal Bank Of Canada initiated coverage on shares of Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price for the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 price target on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $75.70.

Institutional investors and hedge funds have recently bought and sold shares of the stock. QS Investors LLC bought a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $144,000. Teacher Retirement System of Texas bought a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $225,000. S&CO Inc. bought a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $227,000. Cubist Systematic Strategies LLC lifted its position in Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 3,123 shares in the last quarter. Finally, Macquarie Group Ltd. bought a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $245,000. 93.16% of the stock is currently owned by institutional investors and hedge funds.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.